Vol. 4 No. 1 (2018): Conference Proceedings: World Congress on Nutrition and Obesity Prevention Source 2017
Conference Proceedings

poster Combination of Zonisamide and Weight Reduction Program In Obese Schizophrenic Patients

Jye Heon Song
Department of Psychiatry, Naju National Mental Hospital, Naju, Korea
Bo Hyun Yoon
Department of Psychiatry, Naju National Mental Hospital, Naju, Korea
Gwang Hun Lee
Department of Psychiatry, College of Medicine, Dongkuk University, Gyeongju, Korea
Sang Yeol Lee
Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine,
Moon Doo Kim
Department of Psychiatry, Jeju National University School of Medicine, Jeju, Korea
Jeong Seok Seo
Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea
Jung Goo Lee
Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea
Duk In Jon
Department of Psychiatry, Hallym University College of Medicine, Anyang, Korea
Wong Myong Bahk
Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Published January 1, 2018


Objective: Obesity is one of the crucial risk factor for cardiometabolic syndrome in general population as well as in schizophrenicpatients. Zonisamide was known for its weight reducing effect in the treatment of epileptic patients and some bipolar patients.The aim of this study was to investigate the weight reducing effect of zonisamide in combination with weight managementprogram designed for schizophrenic inpatients.

Method: One hundred twenty obese schizophrenic inpatients (BMI>27) were randomly assigned to 4 groups: A, controlgroup (N=19), B, zonisamide alone group (N=34), C, weight reduction program alone group (N=32), and D, combination ofzonisamide and weight reduction group (N=35). Daily dose of zonisamide was 100mg/day. Weight-related variables, laboratorytests and side effects were assessed by monthly intervals for 3 months.

Results: Dropouts were 41 patients during 3 months of trial (group A=7 (41.2%), group B=10 (29.4%), group C=17 (53.1%) andgroup D=7 (20%)). Weight loss was significant in group B, C, D from baseline after 2 month of trial. BMI was also significantlydecreased in group B, C and D. Waist circumferences were significantly decreased in group C and D. Blood pressure and bloodglucose was not changed after 3 months of trial. Blood triglyceride was significantly decreased in group B, C and D. HDLcholesterolwas significantly increased in group B and D. Rash was occurred in 3 patients of zonisamide trial groups (4.3%).Other serious adverse events were not found.

Conclusion: Although the combination of zonisamide and weight reduction program was not superior to drug alone or weightreduction treatment alone, our result showed that zonisamide seems to be safe and effective for weight reducing in obeseschizophrenic inpatients.